Dry Eye DiseasePhase 2NCT05629364
A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease
A Phase 2 study testing KIO-101 in people with Dry Eye Disease, run by Kiora Pharmaceuticals, Inc. at 1 site in Australia.
Trial summary
A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, versus Vehicle Control in the treatment of Dry Eye Disease in Patients with Autoimmune Disease Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Dry Eye Disease
- What is being tested?
- KIO-101
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 4 participants
- Where
- 1 siteAustralia
- Study dates
- 15 Mar 2023to 9 Jan 2024
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have a diagnosis of autoimmune disease (psoriatic arthritis, Systemic Lupus Erythematosus (SLE), or fibromyalgia) ≤ 10 years
- Have an Ocular Discomfort Score (ODS) score of ≥3 at Screening
- Have an average VAS score ≥ 50 at Screening; and ≥ 40 at Baseline, Visit 2/Day 1
- Schirmer's 1 test >1 but < 10 mm at Screening.
- National Eye Institute (NEI) corneal fluorescein staining score of ≥ 4 at Screening (Day 14) provided that the total NEI score did not change > ± 2 grades from Screening (Day -14) to Baseline (Day 1) visits, as confirmed by the investigator
- Have a Best Spectacle Corrected Visual Accuity (BSCVA) score of 20/200 (+1.0 LogMAR) or better in both eyes at both the Screening and Baseline visits
- Have a conjunctival hyperaemia score of Grade 2 or more on the Efron Scale in both eyes
Who cannot join
- Have a history or presence of any ocular disorder or condition (other than dry eye disease (DED)) in either eye that would, in the opinion of the investigator, likely interfere with the interpretation of the study results or subject safety
- Have an autoimmune based vasculitis
- Have a history of RA > 10 years.
- Have a Schirmer's 1 test score of 0 to 1mm at Screening
- Have had a corneal transplant in either or both eyes
- Have had puncta or intracanalicular plug present in either eyelid within 1 year prior to the Screening Visit or anticipated plug insertion or occlusion at any time during the study
Trial locations and contacts
1 site in 1 country.
About this study
A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, versus Vehicle Control in the treatment of Dry Eye Disease in Patients with Autoimmune Disease
- Conditions
- Dry Eye Disease
- Being tested
- KIO-101
- Medical subject headings
- Dry Eye Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
KIO-101Drug
Also called DHODH inhibitor
Randomized, Controlled
| Study group | Role | What they receive |
|---|---|---|
| 0.15% KIO-101 | Experimental | .15% KIO-101 eyedrops Receives: Drug: KIO-101 |
| 0.3% KIO-101 | Experimental | 0.3% KIO-101 eyedrops Receives: Drug: KIO-101 |
| Vehicle | Placebo comparator | Vehicle eyedrops Receives: Drug: KIO-101 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Schirmer's 1 test
Change from Baseline to Week 12 for Schirmer's 1 test
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Nov 2022
- Study start15 Mar 2023
- Primary completion9 Jan 2024
- Study completion9 Jan 2024
Why it stopped: Study halted prematurely but potentially will resume
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dry Eye DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 4 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kiora Pharmaceuticals, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Mark Hinds, Principal investigator, Ophthalmic Trials Australia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05629364
- Sponsor's protocol ID
- KIO-101-2201
- Status last verified
- Jan 2024
- First submitted
- 17 Nov 2022
- Last updated
- 10 Jan 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease
- ClinicalTrials.gov ID
- NCT05629364
- Acronym / sponsor ID
- KIO-101-2201
- Conditions
- Dry Eye Disease
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Study halted prematurely but potentially will resume
- Enrolment
- 4 participants (actual)
- Lead sponsor
- Kiora Pharmaceuticals, Inc.Industry (pharma, biotech, devices)
- Study start
- 15 Mar 2023 (actual)
- Primary completion
- 9 Jan 2024 (actual)
- Study completion
- 9 Jan 2024 (actual)
- First posted
- 29 Nov 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, versus Vehicle Control in the treatment of Dry Eye Disease in Patients with Autoimmune Disease
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 0.15% KIO-101 | Experimental | Drug: KIO-101.15% KIO-101 eyedrops |
| 0.3% KIO-101 | Experimental | Drug: KIO-1010.3% KIO-101 eyedrops |
| Vehicle | Placebo comparator | Drug: KIO-101Vehicle eyedrops |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Have a diagnosis of autoimmune disease (psoriatic arthritis, Systemic Lupus Erythematosus (SLE), or fibromyalgia) ≤ 10 years
- Have an Ocular Discomfort Score (ODS) score of ≥3 at Screening
- Have an average VAS score ≥ 50 at Screening; and ≥ 40 at Baseline, Visit 2/Day 1
- Schirmer's 1 test >1 but < 10 mm at Screening.
- National Eye Institute (NEI) corneal fluorescein staining score of ≥ 4 at Screening (Day 14) provided that the total NEI score did not change > ± 2 grades from Screening (Day -14) to Baseline (Day 1) visits, as confirmed by the investigator
Key exclusion criteria (6 listed)
- Have a history or presence of any ocular disorder or condition (other than dry eye disease (DED)) in either eye that would, in the opinion of the investigator, likely interfere with the interpretation of the study results or subject safety
- Have an autoimmune based vasculitis
- Have a history of RA > 10 years.
- Have a Schirmer's 1 test score of 0 to 1mm at Screening
- Have had a corneal transplant in either or both eyes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| KIO-101Also: DHODH inhibitorRandomized, Controlled | Drug | 0.15% KIO-101, 0.3% KIO-101, Vehicle |
Primary outcome
Change in Schirmer's 1 test
Time frame: 12 weeks
Change from Baseline to Week 12 for Schirmer's 1 test
Results and safety
The study was stopped early (reason given: Study halted prematurely but potentially will resume). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jan 2024.
Related trials for Dry Eye Disease
RecruitingPhase 2
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
Ocular Graft Versus Host Disease
RecruitingPhase 2
An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease
Dry Eye Disease (DED)
Recruiting
Upper Punctal Plug Occlusion in Previous Lower Punctal Occlusion.
DED, Aqueous-deficient Dry Eye Disease
RecruitingObservational study
Association Between Periodontitis and Dry Eye Disease: A Cross-Sectional Study
Periodontitis, Dry Eye Disease (DED)
Not yet recruitingPhase 1
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Systemic Lupus Erythematosus, Sjögren's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mark Hinds principal investigator
Ophthalmic Trials Australia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing KIO-101 in people with Dry Eye Disease, run by Kiora Pharmaceuticals, Inc. at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 10 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Study halted prematurely but potentially will resume). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Schirmer's 1 test (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jan 2024; AzTrials last refreshed its copy on 27 Oct 2026.